March 31, 2008 - PARIS-
BioAlliance Pharma SA (Paris:BIO) announced that it has entered into an exclusive licensing agreement under which Korea-based
Handok Pharmaceuticals will receive commercialization rights in Korea, Taiwan, Singapore and Malaysia.
BioAlliance Pharma's innovative, muco-adhesive antifungal therapy Loramyc
™ (miconazole Lauriad
®) is already approved in Europe and a Phase III clinical trial has just completed in the United States...
[PDF] BioAlliance 's Press Release -
PDF du Communiqué de Presse BioAlliance -
